WaveMan
WaveMan · Company
IOSP · Innospec Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IOSP Innospec (IOSP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Chemicals & allied products · CIK 0001054905
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
150
13F, latest reported quarter

Innospec insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for INNOSPEC INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Jones David B.
SVP, GC & CCO
SELL
2026-03-03 SEC
1,028
$77.8K
+30.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Feb 21, 2025.
  • -9.2% median (-9.2% mean) 90-day return after 2 previous buys.
  • The trade is 7.0% of the 14,693 shares held after it.
  • 5 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, GC & CCO Jones David B. sold about $77.8K of IOSP on Mar 3, 2026; 5 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
Blackmore Milton C
Director
SELL
2026-03-06 SECtraded 2026-02-27
307
$23.6K
+40.5%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Feb 20, 2026.
  • The trade is 2.9% of the 10,530 shares held after it.
  • 5 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Blackmore Milton C sold about $23.6K of IOSP on Feb 27, 2026; 5 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
Blackmore Milton C
Director
SELL
2026-03-06 SECtraded 2026-02-27
287
$21.9K
+40.5%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Feb 20, 2026.
  • The trade is 2.6% of the 10,837 shares held after it.
  • 5 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Blackmore Milton C sold about $21.9K of IOSP on Feb 27, 2026; 5 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
PADFIELD Larry
Director
SELL
2026-03-06 SECtraded 2026-02-27
307
$23.6K
+40.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 20, 2026.
  • The trade is 3.2% of the 9,453 shares held after it.
  • 5 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PADFIELD Larry sold about $23.6K of IOSP on Feb 27, 2026; 5 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
PADFIELD Larry
Director
SELL
2026-03-06 SECtraded 2026-02-27
287
$21.9K
+40.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 20, 2026.
  • The trade is 2.9% of the 9,760 shares held after it.
  • 5 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PADFIELD Larry sold about $21.9K of IOSP on Feb 27, 2026; 5 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
118 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 113 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
150 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
-3.7% year over year
below 61% of Pharma & Biotech
Margin
6.6% net margin
more than 77% of Pharma & Biotech
Buybacks
$13.5M repurchased, FY to 2026-06-30
below 68% of Pharma & Biotech
Short interest
2.0% of the float short (float per yahoo 2026-10-26) · 1.9 days to cover · settled 2026-09-30
below 66% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IOSP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+34.3%12M
-12%+4%+19%+35%2025-102025-122026-022026-042026-062026-082026-10 2026-02-27 · Cleminson Ian sold $182.2K2026-02-27 · Cleminson Ian sold $94.5K2026-02-27 · Cleminson Ian sold $87.7K2026-02-20 · Blackmore Milton C sold $84.3K2026-02-20 · PADFIELD Larry sold $84.3K2026-03-03 · Jones David B. sold $77.8K2026-02-27 · Blackmore Milton C sold $45.5K2026-02-27 · PADFIELD Larry sold $45.5K2026-02-27 · LANDLESS DAVID sold $45.5K2025-11-14 · PARRETTE LESLIE J bought $25.2K2026-02-27 · Blackmore Milton C sold $23.6K2026-02-27 · PADFIELD Larry sold $23.6K2026-02-27 · LANDLESS DAVID sold $23.6K2026-02-27 · Blackmore Milton C sold $21.9K2026-02-27 · PADFIELD Larry sold $21.9K2026-02-27 · LANDLESS DAVID sold $21.9K2026-02-27 · Poccia Claudia sold $9.1K2026-02-27 · Poccia Claudia sold $4.8K2026-02-27 · Poccia Claudia sold $4.3K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IOSP: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,381,323 sh
$356.6M
Allspring Global Investments Holdings, LLC
1,892,471 sh
$154.7M
VANGUARD PORTFOLIO MANAGEMENT LLC
1,884,244 sh
$153.4M
DIMENSIONAL FUND ADVISORS LP
1,305,038 sh
$106.2M
VANGUARD CAPITAL MANAGEMENT LLC
1,108,107 sh
$90.2M

Congress trades in IOSP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IOSP planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IOSP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Allspring Special Small Cap Value Fund
$98.3M position · as of 2026-06-30
3.3%
Brighthouse Small Cap Value Portfolio
$23.5M position · as of 2026-06-30
3.2%
Invesco S&P SmallCap Materials ETF
$567.1K position · as of 2026-05-31
2.7%
Allspring Special Global Small Cap Fund
$2.8M position · as of 2026-07-31
2.5%
Brown Advisory Small-Cap Fundamental Value Fund
$17.8M position · as of 2026-06-30
1.4%
ProShares Russell 2000 Dividend Growers ETF
$7.2M position · as of 2026-05-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Patrick S. Williams
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.3M
$5.5M
$1.4M
-9%
+9%
2024
$13.2M
$11.2M
$2.3M
+28%
+8%
2023
$7.3M
$10.1M
$1.3M
+41%
+10%
2022
$7.9M
$11.2M
$1.4M
+16%
-4%
2021
$9.9M
$6.6M
$1.7M
+1%
+28%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 150 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IOSP financials

Revenue growth
-3.7%
XBRL, annual
Net margin
6.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.8B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+6.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$68.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2021-03-31 (63 months older than the period end) plus current 2020-12-31 (66 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
+9.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+6.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+8.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
20.24x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$2.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2021-03-31 (63 months older than the period end) plus current 2020-12-31 (66 months older than the period end), minus cash 2026-06-30
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.04x
P/E over trailing EPS growth of 528%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.8B$1.8B$1.9B$2.0B
Gross profit$492.4M$542.9M$591.1M$586.7M
Operating income$129.5M$177.9M$161.6M$187.3M
Net income$116.6M$35.6M$139.1M$133.0M
EPS (diluted)4.671.425.565.32
Operating cash flow$138.3M$184.5M$207.3M$81.7M
Cash$292.5M$289.2M$203.7M$147.1M
Buybacks$23.9M$700.0K$1.1M$5.9M
Dividends paid$42.4M$38.8M$35.1M$31.7M
SEC XBRL, fiscal years, as known on 2026-10-28

IOSP Stock Sonar score 5/7 axes

Find similar shapesCompare

IOSP ranks highest on financial health (99th percentile) and profitability (87th), and lowest on growth (39th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
87
Inputs
  • Return on equity+9.2% · 85 pct, sector of 545
  • Return on assets+6.7% · 87 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+8.7% · 90 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
39
Inputs
  • Revenue growth, YoY-3.7% · 39 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
81
Inputs
  • Funds adding, latest quarter150 · 81 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
85
Inputs
  • Short interest, % of float+2.0% · 74 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+2.0% · 95 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies